These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Author: Cunnick G, Mokbel K.
    Journal: Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468.
    Abstract:
    There is a growing body of evidence that the optimal adjuvant endocrine therapy for hormone-sensitive breast cancer in postmenopausal women should include an aromatase inhibitor. However, further research is required to establish the optimal aromatase inhibitor and whether such a drug should be used as monotherapy or in sequence after 2 to 3 years of tamoxifen.
    [Abstract] [Full Text] [Related] [New Search]